MedTrace Logo

Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above

NCT07285265 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-05-11

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of 2 injections (approximately 2 months apart) of three different dose levels of ABO1108 in adults aged 40 years or above.

Conditions

  • Varicella-zoster Virus

Interventions

BIOLOGICAL

ABO1108

Formulation for injection

DRUG

Placebo

0.9% sodium chloride (normal saline) injection

BIOLOGICAL

SHINGRIX

• Formulation for injection

Sponsors & Collaborators

  • Abogen Biosciences (Shanghai) Co., Ltd

    collaborator INDUSTRY

  • Suzhou Abogen Biosciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-27
Primary Completion
2025-11-06
Completion
2026-10-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07285265 on ClinicalTrials.gov